Clinical insights from diagnosis to outcomes in pediatric hypoparathyroidism and inactivating PTH/PTHrP signaling disorders

OBJECTIVE: This study retrospectively evaluated the clinical, laboratory, and treatment characteristics of pediatric patients with hypoparathyroidism (HP) or inactivating PTH/PTHrP signaling disorders (iPPSD), focusing on metabolic parameters and long-term outcomes. SUBJECTS AND METHODS: Twenty-three children with HP or iPPSD were included. Clinical, biochemical, and therapeutic data were assessed at diagnosis, after one year, and at the last follow-up. HP cases were classified as postsurgical or non-surgical. RESULTS: = 0.02), and no renal complications were observed. CONCLUSION: Pediatric HP and iPPSD show distinct profiles. Serum calcium levels increased during follow-up in the iPPSD and non-surgical HP groups, while postsurgical HP patients achieved normocalcemia more rapidly. In the iPPSD group, reductions in serum phosphorus and PTH levels suggested effective long-term biochemical control. Oral calcium supplementation decreased over time in iPPSD and non-surgical HP, whereas calcitriol doses remained stable, and no renal complications were observed, supporting the safety of current treatment strategies.